Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tenofovir disoproxil orotate
- Development stage
- Phase 3
- Lead developer
- Dong-A ST
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tenofovir disoproxil orotate (DA-2802) is an oral small molecule nucleotide reverse transcriptase inhibitor developed for the treatment of chronic hepatitis B. It is a novel salt form of tenofovir prodrug, similar in mechanism to tenofovir disoproxil fumarate (TDF), and works by inhibiting hepatitis B virus (HBV) replication through chain termination during viral DNA synthesis. Clinical trials have demonstrated that DA-2802 is non-inferior to TDF in reducing HBV DNA levels and has a comparable safety profile, with most adverse events being mild to moderate. The drug was developed by Dong-A ST and has completed phase III clinical trials in South Korea for chronic hepatitis B[1][2][3][4][5].
- Other names
- tenofovir disoproxil orotateDA 2802DA2802DA-2802
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseHBV Pol (Hepatitis B virus polymerase)POLA1 (DNA polymerase alpha)DNA polymerase family
Beyond the preview
Go deeper on tenofovir disoproxil orotate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tenofovir disoproxil orotate.